Bavarian Nordic A/S (BVNRY)
USD 9.23
(-0.22%)
USD 9.23
(-0.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.05 Billion DKK | 39047.28% |
| 2022 | -3.84 Million DKK | 98.54% |
| 2021 | -263.31 Million DKK | -158.56% |
| 2020 | 449.62 Million DKK | 242.09% |
| 2019 | -316.43 Million DKK | 10.73% |
| 2018 | -354.48 Million DKK | -200.36% |
| 2017 | 353.19 Million DKK | 970.06% |
| 2016 | 33 Million DKK | 2024.0% |
| 2015 | 1.55 Million DKK | -90.68% |
| 2014 | 16.67 Million DKK | -50.1% |
| 2013 | 33.41 Million DKK | 205.47% |
| 2012 | -31.68 Million DKK | 89.72% |
| 2011 | -308.26 Million DKK | 34.98% |
| 2010 | -474.08 Million DKK | -38.95% |
| 2009 | -341.18 Million DKK | -52.73% |
| 2008 | -223.38 Million DKK | -243.53% |
| 2007 | -65.02 Million DKK | 68.09% |
| 2006 | -203.76 Million DKK | -70.13% |
| 2005 | -119.77 Million DKK | -45.49% |
| 2004 | -82.32 Million DKK | -138.46% |
| 2003 | 214.03 Million DKK | 903.15% |
| 2002 | -26.65 Million DKK | 71.49% |
| 2001 | -93.48 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 265.89 Million DKK | 306.29% |
| 2024 Q1 | -92.16 Million DKK | -114.09% |
| 2023 FY | 1.49 Billion DKK | 39047.28% |
| 2023 Q4 | 914.83 Million DKK | 376.31% |
| 2023 Q1 | 374.93 Million DKK | 52.06% |
| 2023 Q3 | -331.09 Million DKK | -159.1% |
| 2023 Q2 | 560.2 Million DKK | 49.41% |
| 2022 Q3 | 129.24 Million DKK | 178.52% |
| 2022 Q4 | 246.56 Million DKK | 90.77% |
| 2022 Q1 | -173.09 Million DKK | -209.55% |
| 2022 Q2 | -164.59 Million DKK | 4.91% |
| 2022 FY | -3.84 Million DKK | 98.54% |
| 2021 Q1 | -87.99 Million DKK | 75.15% |
| 2021 Q3 | -46.98 Million DKK | 55.94% |
| 2021 FY | -263.31 Million DKK | -158.56% |
| 2021 Q4 | -55.91 Million DKK | -19.01% |
| 2021 Q2 | -106.64 Million DKK | -21.19% |
| 2020 Q2 | 112.21 Million DKK | -79.88% |
| 2020 Q1 | 557.58 Million DKK | 1921.17% |
| 2020 Q4 | -354.15 Million DKK | -653.88% |
| 2020 FY | 449.62 Million DKK | 242.09% |
| 2020 Q3 | 63.94 Million DKK | -43.02% |
| 2019 Q4 | -30.61 Million DKK | 68.27% |
| 2019 Q1 | -104.3 Million DKK | -11.49% |
| 2019 Q2 | -97.01 Million DKK | 6.99% |
| 2019 FY | -316.43 Million DKK | 10.73% |
| 2019 Q3 | -96.5 Million DKK | 0.53% |
| 2018 Q2 | -107.01 Million DKK | 38.09% |
| 2018 Q4 | -93.55 Million DKK | -593.27% |
| 2018 Q1 | -172.87 Million DKK | 2.91% |
| 2018 FY | -354.48 Million DKK | -200.36% |
| 2018 Q3 | 18.96 Million DKK | 117.72% |
| 2017 Q3 | 432.01 Million DKK | 322.1% |
| 2017 Q4 | -178.05 Million DKK | -141.21% |
| 2017 FY | 353.19 Million DKK | 970.06% |
| 2017 Q1 | -3.11 Million DKK | -102.71% |
| 2017 Q2 | 102.34 Million DKK | 3381.47% |
| 2016 Q1 | -152.74 Million DKK | -22101.31% |
| 2016 Q2 | -54.04 Million DKK | 64.62% |
| 2016 FY | 33 Million DKK | 2024.0% |
| 2016 Q3 | 124.83 Million DKK | 330.99% |
| 2016 Q4 | 114.96 Million DKK | -7.91% |
| 2015 FY | 1.55 Million DKK | -90.68% |
| 2015 Q4 | -688 Thousand DKK | 99.17% |
| 2015 Q3 | -82.52 Million DKK | -166.02% |
| 2015 Q2 | 125 Million DKK | 410.95% |
| 2015 Q1 | -40.2 Million DKK | -129.14% |
| 2014 Q3 | -51.6 Million DKK | 29.41% |
| 2014 Q4 | 137.97 Million DKK | 367.39% |
| 2014 FY | 16.67 Million DKK | -50.1% |
| 2014 Q1 | 3.4 Million DKK | -91.37% |
| 2014 Q2 | -73.1 Million DKK | -2250.0% |
| 2013 Q2 | 10 Million DKK | 121.01% |
| 2013 Q3 | 31.6 Million DKK | 216.0% |
| 2013 Q4 | 39.41 Million DKK | 24.73% |
| 2013 FY | 33.41 Million DKK | 205.47% |
| 2013 Q1 | -47.6 Million DKK | 13.27% |
| 2012 Q3 | 34 Million DKK | 78.95% |
| 2012 Q2 | 19 Million DKK | 163.76% |
| 2012 Q4 | -54.88 Million DKK | -261.41% |
| 2012 FY | -31.68 Million DKK | 89.72% |
| 2012 Q1 | -29.8 Million DKK | -216.7% |
| 2011 Q4 | 25.53 Million DKK | 132.16% |
| 2011 Q3 | -79.4 Million DKK | 41.05% |
| 2011 FY | -308.26 Million DKK | 34.98% |
| 2011 Q2 | -134.7 Million DKK | -12.53% |
| 2011 Q1 | -119.7 Million DKK | -19.24% |
| 2010 Q3 | -185.8 Million DKK | -161.32% |
| 2010 FY | -474.08 Million DKK | -38.95% |
| 2010 Q4 | -100.38 Million DKK | 45.97% |
| 2010 Q2 | -71.1 Million DKK | 39.23% |
| 2010 Q1 | -117 Million DKK | -18.32% |
| 2009 Q3 | -74.1 Million DKK | 30.62% |
| 2009 Q4 | -98.88 Million DKK | -33.45% |
| 2009 FY | -341.18 Million DKK | -52.73% |
| 2009 Q2 | -106.8 Million DKK | -20.54% |
| 2009 Q1 | -88.6 Million DKK | 0.0% |
| 2008 FY | -223.38 Million DKK | -243.53% |
| 2007 FY | -65.02 Million DKK | 68.09% |
| 2006 FY | -203.76 Million DKK | -70.13% |
| 2005 FY | -119.77 Million DKK | -45.49% |
| 2004 FY | -82.32 Million DKK | -138.46% |
| 2003 FY | 214.03 Million DKK | 903.15% |
| 2002 FY | -26.65 Million DKK | 71.49% |
| 2001 FY | -93.48 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 2961.763% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -41699.064% |
| SQZ Biotechnologies Company | -75.82 Million USD | 2809.324% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 11610.87% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -2409.832% |
| Mesoblast Limited | -84.14 Million USD | 2541.376% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 133842.153% |
| Genus plc | 6.4 Million USD | -31999.141% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -20986.514% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 220670.014% |
| Marizyme, Inc. | -34.08 Million USD | 6126.855% |
| ContraFect Corporation | -56.88 Million USD | 3711.146% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 24702.934% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 45203.591% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 146630.541% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 72169.46% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 74780.67% |
| MultiCell Technologies, Inc. | -722.81 USD | 284216560.757% |
| Accustem Sciences Inc. | -3.74 Million USD | 54934.897% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 3582.531% |
| EV Biologics, Inc. | -483.06 Thousand USD | 425375.637% |
| Q BioMed Inc. | -3.44 Million USD | 59721.995% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -57932.345% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 527436.551% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 78285.644% |
| Biomind Labs Inc. | -1 Million USD | 203580.477% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 42201.168% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 31001.63% |
| Skye Bioscience, Inc. | -13.67 Million USD | 15126.149% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 103516.397% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 6858890.732% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 40824.59% |
| IMV Inc. | -38.67 Million USD | 5412.295% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 13045.048% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 106398.995% |
| GB Sciences, Inc. | -1.42 Million USD | 144720.344% |
| Alpha Cognition Inc. | -9.7 Million USD | 21266.592% |
| HST Global, Inc. | -140.9 Thousand USD | 1458043.892% |
| CSL Limited | 3.7 Billion USD | 44.507% |
| Halberd Corporation | -75.05 Thousand USD | 2737401.799% |
| Enzolytics Inc. | -2.14 Million USD | 95704.291% |
| Resverlogix Corp. | -12.74 Million USD | 16213.774% |
| Affymax, Inc. | -15.04 Million USD | 13753.762% |
| SYBLEU INC | -149.18 Thousand USD | 1377191.433% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 64941.141% |
| argenx SE | -425.04 Million USD | 583.32% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 3800.989% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 196876.341% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 130174.936% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 60433.559% |
| AVAX Technologies, Inc. | 6.69 Million USD | -30594.484% |
| Zenith Capital Corp. | -8.94 Million USD | 23071.542% |
| Genscript Biotech Corporation | -415.79 Million USD | 594.081% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 11792448.315% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 83769.237% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 1197902.175% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 3837.051% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 70908.962% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 208863.654% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 110289.769% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 163662.5% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 102573.517% |
| BioStem Technologies, Inc. | -7.77 Million USD | 26508.962% |
| ONE Bio Corp. | 13.68 Million USD | -14915.442% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 1132064.074% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 153933.856% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 182723.704% |
| Agentix Corp. | -1.37 Million USD | 149860.234% |
| LadRx Corporation | -3.82 Million USD | 53827.666% |
| Cell Source, Inc. | -4.32 Million USD | 47595.507% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 494552.187% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 299153.061% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 299153.061% |
| NovAccess Global Inc. | -2.46 Million USD | 83381.106% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 70467.68% |
| Itoco Inc. | -919.14 Thousand USD | 223607.3% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 48569.663% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 183687.578% |
| Kadimastem Ltd | -3.04 Million USD | 67671.581% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 785022.018% |
| CytoDyn Inc. | -18.05 Million USD | 11476.371% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 8161979.221% |
| Mobile Lads Corp. | -554.55 Thousand USD | 370552.619% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 933562.227% |
| Qrons Inc. | -643.67 Thousand USD | 319257.745% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 363879.233% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 92228.093% |
| Rebus Holdings, Inc. | -664 Thousand USD | 309489.307% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 113204.794% |
| International Stem Cell Corporation | -663 Thousand USD | 309955.958% |
| Bioxytran, Inc. | -3.82 Million USD | 53876.596% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 3902731.079% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 10100124.582% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 5764.658% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 127068.171% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 279285.551% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 66134.876% |
| Neutra Corp. | -229.48 Thousand USD | 895294.042% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 11813.011% |
| PureTech Health plc | -146.19 Million USD | 1505.17% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 9659.041% |
| IXICO plc | -1.43 Million USD | 143060.682% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 21745.19% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 1786.571% |
| CSL Limited | 3.81 Billion USD | 46.108% |
| Cellectis S.A. | -108.85 Million USD | 1987.19% |